Eight gene mutation-based polygenic hazard score as a potential predictor for immune checkpoint inhibitor therapy outcome in metastatic melanoma

Background: Immune checkpoint inhibitor (ICI) therapies have revolutionized the treatment of metastatic cutaneous melanoma, but have only benefitted a subset of them. Gene mutations were reported to impact the ICI therapy outcomes in metastatic melanoma but have not been fully investigated. Hence, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Liqin, Luo, Ting, Jiang, Jinling, Wu, Junwei, Zhang, Xiaowei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478752/
https://www.ncbi.nlm.nih.gov/pubmed/36120536
http://dx.doi.org/10.3389/fmolb.2022.1001792

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478752/
https://www.ncbi.nlm.nih.gov/pubmed/36120536
http://dx.doi.org/10.3389/fmolb.2022.1001792

Ejemplares similares